Results 101 to 110 of about 12,272 (191)

Prospects of Using PCSK9 Inhibitors for Acute Coronary Syndrome

Инновационная медицина Кубани
Proprotein convertase subtilisin/kexin type 9 (PCSK9) is an enzyme involved in the regulation of blood cholesterol levels by binding to low-density lipoprotein receptors and promoting their degradation. Pivotal studies have shown that PCSK9 inhibition by
A. M. Namitokov, V. K. Zafiraki, K. V. Karabakhtsieva   +2 more
doaj   +1 more source

Efficacy and safety of PCSK-9 inhibitors in patients with acute coronary syndrome: a systematic review and network meta-analysis

BMC Cardiovascular Disorders
Background Acute coronary syndrome (ACS) remains a leading cause of global cardiovascular morbidity and mortality, with elevated low-density lipoprotein cholesterol (LDL-C) being a key modifiable risk factor. Despite statin therapy, many patients fail to
Guoying Kao, Chuan Chen, Ying Zhang, Yi Xu, Gang Xu   +4 more
doaj   +1 more source

Impact of national drug price negotiation policy on the accessibility and utilization of PCSK9 inhibitors in China: an interrupted time series analysis

International Journal for Equity in Health
Background PCSK9 inhibitors are a novel class of lipid-lowering drugs that have demonstrated favorable efficacy and safety. Evolocumab and alirocumab have been added to China’s National Reimbursement Drug List through the National Drug Price Negotiation (
Lingli Zhang, Xiaoye Wang, Hongting Yao, Baolong Ding, Xingyuan Gao, Xin Li   +5 more
doaj   +1 more source

PCSK9 in peripheral arterial disease: Mechanisms and therapeutic perspectives

Science Progress
This narrative review comprehensively examines the multifaceted roles of proprotein convertase subtilisin/kexin type 9 (PCSK9) in peripheral arterial disease (PAD).
Yue Gao, Jing Zhang, Nan Jiang, Lijuan Wang, Tingbing Cao, Yangli Xie, Hongbo He, Li Li   +7 more
doaj   +1 more source

PCSK9 inhibition in the management of hyperlipidemia: focus on evolocumab

Vascular Health and Risk Management, 2016
Dirk J Blom,1 Ricardo Dent,2 Rita C Castro,2 Peter P Toth3,4 1Division of Lipidology, Department of Medicine, University of Cape Town, Cape Town, South Africa; 2Amgen, Inc., Thousand Oaks, CA, 3Ciccarone Center for the Prevention of Cardiovascular ...
Blom DJ, Dent R, Castro RC, Toth PP
doaj  

A narrative review of PCSK9 inhibitors: from evolocumab to novel discoveries. [PDF]

Front Pharmacol
Liu HH, Li S, Li JJ.
europepmc   +1 more source

Enzyme-Assisted Synthesis and In Vitro Characterization of Bifunctional PCSK9 Inhibitors. [PDF]

Chembiochem
Zhang Y, Wang L, Corcilius L, Reji AK, Payne RJ, Hong B, Durek T, Wang CK, Craik DJ.   +8 more
europepmc   +1 more source

PCSK9 Inhibitors Reduce Oxidative Stress Biomarkers in Heterozygous Familial Hypercholesterolemia. [PDF]

J Cell Mol Med
Woźniak-Szczepocka A, Pawlos A, Gorzelak-Pabiś P, Broncel M, Bukowska B, Woźniak E.   +5 more
europepmc   +1 more source

Adherence to PCSK9 Inhibitors in Clinical Practice: Systematic Review and Meta-Analysis of Observational Studies. [PDF]

JACC Adv
Blais JE, Zhong W, Li CYV, Kongkaew C, Chan AHY.   +4 more
europepmc   +1 more source

Novel Approaches to Lipid Management: Beyond Statins and PCSK9 Inhibitors. [PDF]

J Clin Med Res
Patel J, Shah S, Reddy A, Prajapati D, Pandya A, Sawhney S.   +5 more
europepmc   +1 more source